4.7 Article

Impact of COVID-19 pandemic on eye cancer care in United Kingdom

期刊

BRITISH JOURNAL OF CANCER
卷 124, 期 8, 页码 1357-1360

出版社

SPRINGERNATURE
DOI: 10.1038/s41416-021-01274-4

关键词

-

类别

资金

  1. National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust
  2. UCL Institute of Ophthalmology

向作者/读者索取更多资源

The UK Ocular Oncology Services conducted a study on the impact of COVID-19 pandemic on adult eye cancer care in the UK, finding significant reductions in referral and diagnosis numbers during the lockdown period. The study also revealed shifts in treatment choices and an increase in advanced disease cases after the lockdown was lifted.
The COVID-19 pandemic has had an unprecedented impact on the National Health Service in United Kingdom. The UK Ocular Oncology Services evaluated the impact on the adult eye cancer care in the UK. All four adult Ocular Oncology centres participated in a multicentre retrospective review comparing uveal melanoma referral patterns and treatments in a 4-month period during the national lockdown and first wave of the COVID-19 pandemic in 2020 with corresponding periods in previous 2 years. During the national lockdown, referral numbers and confirmed uveal melanoma cases reduced considerably, equalling to similar to 120 fewer diagnosed uveal melanoma cases compared to previous 2 years. Contrary to the recent trend, increased caseloads of enucleation and stereotactic radiosurgery (p > 0.05), in comparison to fewer proton beam therapy (p < 0.05), were performed. In the 4-month period following lockdown, there was a surge in clinical activities with more advanced diseases (p < 0.05) presenting to the services. As the COVID-19 pandemic continues to mount pressure and reveal its hidden impact on the eye cancer care, it is imperative for the Ocular Oncology Services to plan recovery strategies and innovative ways of working.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据